AU2001235669A1 - Use of xanthine derivatives for preparing a medicine for preventing and treatingosteoporosis - Google Patents

Use of xanthine derivatives for preparing a medicine for preventing and treatingosteoporosis

Info

Publication number
AU2001235669A1
AU2001235669A1 AU2001235669A AU3566901A AU2001235669A1 AU 2001235669 A1 AU2001235669 A1 AU 2001235669A1 AU 2001235669 A AU2001235669 A AU 2001235669A AU 3566901 A AU3566901 A AU 3566901A AU 2001235669 A1 AU2001235669 A1 AU 2001235669A1
Authority
AU
Australia
Prior art keywords
medicine
preparing
preventing
treatingosteoporosis
xanthine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235669A
Other languages
English (en)
Inventor
Gunter Johannes Billen
Yamina Bouali
Yusuke Satoh
Jean-Paul Vevert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2001235669A1 publication Critical patent/AU2001235669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2001235669A 2000-02-15 2001-02-14 Use of xanthine derivatives for preparing a medicine for preventing and treatingosteoporosis Abandoned AU2001235669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0001846 2000-02-15
FR0001846A FR2804867B1 (fr) 2000-02-15 2000-02-15 Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
PCT/FR2001/000421 WO2001060372A2 (fr) 2000-02-15 2001-02-14 Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
AU2001235669A1 true AU2001235669A1 (en) 2001-08-27

Family

ID=8847005

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001235669A Abandoned AU2001235669A1 (en) 2000-02-15 2001-02-14 Use of xanthine derivatives for preparing a medicine for preventing and treatingosteoporosis

Country Status (9)

Country Link
EP (1) EP1263444B1 (fr)
AT (1) ATE300304T1 (fr)
AU (1) AU2001235669A1 (fr)
DE (1) DE60112253T2 (fr)
DK (1) DK1263444T3 (fr)
ES (1) ES2242731T3 (fr)
FR (1) FR2804867B1 (fr)
PT (1) PT1263444E (fr)
WO (1) WO2001060372A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017684A2 (fr) * 1992-03-04 1993-09-16 Cell Therapeutics, Inc. Composes a base de xanthine hydroxylee enantiomere
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
JPH09169665A (ja) * 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
EP0812844B1 (fr) * 1996-06-07 2002-10-23 Hoechst Aktiengesellschaft Utilisation de dérivés de théophylline pour la prophylaxie et le traitement des conditions de choc, nouveaux composés à base de xanthine et leurs procédés de préparation
JPH1192379A (ja) * 1997-07-24 1999-04-06 Kunio Takaoka 骨疾患の予防または治療剤

Also Published As

Publication number Publication date
EP1263444B1 (fr) 2005-07-27
PT1263444E (pt) 2005-10-31
ES2242731T3 (es) 2005-11-16
ATE300304T1 (de) 2005-08-15
EP1263444A2 (fr) 2002-12-11
DE60112253D1 (de) 2005-09-01
FR2804867A1 (fr) 2001-08-17
FR2804867B1 (fr) 2002-09-20
WO2001060372A3 (fr) 2002-04-11
WO2001060372A2 (fr) 2001-08-23
DK1263444T3 (da) 2005-11-14
DE60112253T2 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2001046200A8 (fr) Nouveaux derives de piperidine et de piperazine
AU5242000A (en) Nematicidal trifluorobutenes
SE9904505D0 (sv) Novel compounds
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
AU2001264474A1 (en) Admantane derivatives
AU2002249890A1 (en) Carboline derivatives
AU2002239348A1 (en) Pyrazolopyridine derivatives
AU2002213421A1 (en) Condensed pyridoindole derivatives
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
MXPA03010761A (es) Combinaciones farmaceuticas.
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
GB0109122D0 (en) Novel compounds
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
IL150061A0 (en) Purine derivatives
AU2002213419A1 (en) Condensed pyridoindole derivatives
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
WO2001010860A3 (fr) Derives de quinazolinone et d'azaquinazolinone
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
WO2001060343A3 (fr) Utilisation d'acide 2-methyl-thiazolidin-2,4-dicarboxylique (2-mtdc) et/ou de ses sels physiologiquement compabibles pour le traitement et/ou la prevention de cancers